Franklin Resources Inc. lowered its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 17.7% during the 4th quarter, HoldingsChannel.com reports. The fund owned 2,175,586 shares of the medical research company’s stock after selling 466,486 shares during the quarter. Franklin Resources Inc.’s holdings in Amgen were worth $712,091,000 at the end of the most recent reporting period.
A number of other large investors have also recently modified their holdings of AMGN. Erste Asset Management GmbH grew its holdings in shares of Amgen by 70.1% during the fourth quarter. Erste Asset Management GmbH now owns 156,728 shares of the medical research company’s stock worth $51,658,000 after purchasing an additional 64,566 shares in the last quarter. Brandywine Global Investment Management LLC lifted its position in Amgen by 15.6% during the fourth quarter. Brandywine Global Investment Management LLC now owns 427,722 shares of the medical research company’s stock valued at $139,998,000 after purchasing an additional 57,626 shares during the last quarter. O Shaughnessy Asset Management LLC grew its stake in Amgen by 25.7% in the 4th quarter. O Shaughnessy Asset Management LLC now owns 132,386 shares of the medical research company’s stock worth $43,331,000 after buying an additional 27,035 shares in the last quarter. Hilton Head Capital Partners LLC bought a new position in shares of Amgen in the 4th quarter worth $1,243,000. Finally, HFR Wealth Management LLC increased its holdings in shares of Amgen by 0.6% in the 4th quarter. HFR Wealth Management LLC now owns 38,664 shares of the medical research company’s stock worth $12,655,000 after buying an additional 214 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.
Insider Activity at Amgen
In related news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.85% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
View Our Latest Research Report on Amgen
Amgen Trading Down 1.1%
NASDAQ:AMGN opened at $345.66 on Tuesday. The firm has a market capitalization of $186.56 billion, a P/E ratio of 24.05, a P/E/G ratio of 3.51 and a beta of 0.42. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The company has a fifty day moving average of $341.20 and a 200 day moving average of $345.51. Amgen Inc. has a 52 week low of $267.83 and a 52 week high of $391.29.
Amgen (NASDAQ:AMGN – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The firm had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts predict that Amgen Inc. will post 22.38 earnings per share for the current year.
Amgen Company Profile
Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.
Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.
Featured Articles
- Five stocks we like better than Amgen
- 3 Stocks With Fresh Catalysts to Watch Before the July 4
- Amprius Insiders Are Selling: Should Investors Be Worried?
- A Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus
- A Market Rotation Toward Quality Will Benefit These 3 ETFs
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
